Short interest for Sage Therapeutics gives investors a sense of the degree to which investors are betting on the decline of Sage Therapeutics's stock. Short interest data is updated every two weeks.

Sage Therapeutics Stock (NASDAQ:SAGE), Short Interest Report

Sage Therapeutics

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

Hilton hotel sign

BILI

CGEM

LWAY

NVTS

RBBN

RILY

SAGE

TSLA

Hilton Worldwide Reports Upbeat Results, Joins Hasbro, Vertiv Holdings And Other Big Stocks Moving Higher On Wednesday

Television,Streaming,,Tv,Broadcast.,Multimedia,Wall,Concept.

News

Pre-Market Outlook

Markets

Movers

ADPT

CRML

DCGO

NFLX

NOVA

Netflix, ON Semiconductor And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

Earnings

Penny Stocks

Eurozone

Commodities

Small Cap

Global

Intraday Update

Trading Ideas

EDBL

INVO

LGVN

OTRK

VNDA

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Wednesday.

The Dow traded up 0.04% to 37,813.77 while the NASDAQ fell 0.78% to 15,742.21. The S&amp;P 500 also fell, dropping, 0.34% to 5,034.17.

Crude Oil Dips 3%; U.S. Bancorp Profit Tops Views

Sage Therapeutics Inc

Sage Gold Inc

Sage Group (The) PLC

SAGE GROUP UNSP/ADR by Sage Group plc (The)

Sage Potash Corp

SAGEN MI CDA INC PFD A by SAGEN MI CDA INC.

Sagen MI Canada Inc

HC Wainwright &amp; Co. analyst Douglas Tsao maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Neutral and lowers the price target from $28 to $25.

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Neutral on Sage Therapeutics, Lowers Price Target to $25

Goldman Sachs analyst Salveen Richter maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Neutral and lowers the price target from $28 to $19.

Goldman Sachs Maintains Neutral on Sage Therapeutics, Lowers Price Target to $19

RBC Capital analyst Brian Abrahams maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Sector Perform and lowers the price target from $26 to $15.

RBC Capital Maintains Sector Perform on Sage Therapeutics, Lowers Price Target to $15

Truist Securities analyst Joon Lee maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Hold and lowers the price target from $22 to $18.

Truist Securities Maintains Hold on Sage Therapeutics, Lowers Price Target to $18

Mizuho analyst Uy Ear maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Neutral and lowers the price target from $20 to $18.

Mizuho Maintains Neutral on Sage Therapeutics, Lowers Price Target to $18

Canaccord Genuity analyst Sumant Kulkarni maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Hold and lowers the price target from $21 to $17.

Canaccord Genuity Maintains Hold on Sage Therapeutics, Lowers Price Target to $17

Needham analyst Ami Fadia reiterates Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Hold.

Reiteration

Needham Reiterates Hold on Sage Therapeutics

<div>The Company does not anticipate receipt of any additional milestone payments from collaborations in the remainder of 2024.&nbsp;The Company anticipates operating expenses will decrease in 2024 relative to 2023.​&nbsp;With the availability of ZURZUVAE in the U.S. as an additional treatment for women with PPD, the Company anticipates ZULRESSO revenues will continue to decrease over time.</div>

Guidance

Sage Therapeutics Expects Cash & Equivalents Plus Funding To Support Its Operations Into 2026; Expects ZULRESSO Revenues To Continue To Decrease Over Time

Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) reported quarterly losses of $(1.80) per share which missed the analyst consensus estimate of $(1.65) by 9.09 percent. The company reported quarterly sales of $7.902 million which beat the analyst consensus estimate of $5.658 million by 39.65 percent. This is a 139.89 percent increase over sales of $3.294 million the same period last year.

Earnings Beats

Earnings Misses

Sage Therapeutics Q1 2024 GAAP EPS $(1.80) Misses $(1.65) Estimate, Sales $7.902M Beat $5.658M Estimate

U.S. stocks were mixed, with the Dow Jones falling over 100 points on Wednesday.
Shares of Hilton Worldwide Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) rose sharply during Wednesday's session after the company reported better-than-expected first-quarter financial results and raised FY24 <a href="https://www.benzinga.com/news/earnings/24/04/38402048/hilton-stock-is-jumping-post-q1-results-heres-why">adjusted EPS guidance.</a>
Hilton Worldwide shares gained 5.7% to $208.21 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>B. Riley Financial, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>) shares gained 29.9% to $28.20 after the company announced the results of an independent investigation showed the company and its executives had no involvement with, or knowledge of, any of the alleged misconduct concerning Mr. Kahn or any of his affiliates.</li>
<li>MMTec, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) shares jumped 29% to $2.8948.</li>
<li>Ribbon Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBBN#NASDAQ">RBBN</a>) shares climbed 27.2% to $3.2699 after the company reported first-quarter financial results and issued guidance.</li>
<li>Hasbro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>) gained 12.1% to $65.13 following better-than-expected first-quarter financial results.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rose 11.9% to $161.93 following first-quarter results.</li>
<li>Vertiv Holdings Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) gained 11.2% to $88.07 after the company reported better-than-expected first-quarter financial results and raised its 2024 guidance.</li>
<li>Bilibili Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>) gained 11% to $12.76.</li>
<li>Lifeway Foods, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWAY#NASDAQ">LWAY</a>) gained 9.9% to $22.50.</li>
<li>Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) rose 9.2% to $4.1402. Navitas Semiconductor is expected to report first-quarter financial results on Thursday, May 9.</li>
<li>Westinghouse Air Brake Technologies Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAB#NYSE">WAB</a>) gained 9% to $161.84 after the company reported better-than-expected first-quarter financial results and raised its 2024 guidance.</li>
<li>Stride, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LRN#NYSE">LRN</a>) gained 8.4% to $63.07 after the company reported better-than-expected third-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>Cullinan Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>) gained 8% to $18.00.</li>
<li>Sage Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) jumped 7.7% to $13.95.</li>
<li>Texas Instruments Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) gained 6.4% to $176.10 following a first-quarter earnings beat.</li>
<li>Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) rose 6.2% to $73.24 after the company reported better than expected first-quarter earnings and issued guidance.</li>
<li>Watsco, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSO#NYSE">WSO</a>) gained 6.2% to $439.17 following first-quarter results.</li>
<li>Group 1 Automotive, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPI#NYSE">GPI</a>) jumped 6.1% to $296.67 after the company reported better-than-expected first-quarter financial results.</li>
</ul>
Read More: Meta Likely To Report Higher Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts

<h3>Gainers</h3>
<ul>
<li>Immutep (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMP#NASDAQ">IMMP</a>) stock increased by 15.5% to $2.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $344.7 million. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) stock rose 14.96% to $1.14. The market value of their outstanding shares is at $7.4 million. </li>
<li>Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares increased by 13.12% to $14.65. The company's market cap stands at $880.5 million. </li>
<li>Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) shares moved upwards by 12.72% to $8.68. The market value of their outstanding shares is at $2.0 billion. </li>
<li>Viracta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRX#NASDAQ">VIRX</a>) stock moved upwards by 12.05% to $0.95. The company's market cap stands at $37.3 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock moved upwards by 11.87% to $0.55. The company's market cap stands at $30.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) shares declined by 32.2% to $5.19 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.8 billion. The company's, Q4 earnings came out today. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) stock decreased by 17.29% to $0.21. The market value of their outstanding shares is at $2.7 million. </li>
<li>Ovid Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OVID#NASDAQ">OVID</a>) stock declined by 15.32% to $2.71. The company's market cap stands at $191.6 million. </li>
<li>BiomX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PHGE#AMEX">PHGE</a>) stock decreased by 14.23% to $0.3. The company's market cap stands at $16.4 million. </li>
<li>Kiora Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPRX#NASDAQ">KPRX</a>) stock decreased by 13.84% to $0.5. The market value of their outstanding shares is at $13.1 million. </li>
<li>Addex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) stock declined by 13.72% to $16.17. The market value of their outstanding shares is at $17.2 million. The company's, Q4 earnings came out 4 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADXN

BIVI

IMMP

Kiora Pharmaceuticals, Inc. - Common Stock

KPRX

LUCY

OVID

PHGE

RXRX

SYRA

VIRX

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

U.S. stock futures were lower this morning, with the Nasdaq futures declining over 100 points on Friday.
Shares of Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) fell sharply in today's pre-market trading following <a href="https://www.benzinga.com/news/earnings/24/04/38324337/netflix-q1-earnings-highlights-revenue-beat-eps-beat-9-33-million-paid-subs-added-ad-tier-plan-upda">first-quarter results.</a>
Netflix reported upbeat earnings and sales results for its first quarter. The company added 9.33 million paid net new subscribers in the first quarter to bring the company to a total of 269.60 million.
Netflix shares fell 6% to $573.81 pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Critical Metals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRML#NASDAQ">CRML</a>) shares fell 12.3% to $7.37 in pre-market trading after surging 12% on Thursday.</li>
<li>Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) shares declined 11.4% to $2.07 in pre-market trading. Adaptive Biotechnologies is expected to report financial results for the first quarter 2024 after the closing bell on May 7, 2024.</li>
<li>Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) fell 6.1% to $27.40 in pre-market trading.</li>
<li>SAGE Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares declined 5.6% to $12.30 in pre-market trading. The company recently announced topline results from Phase 2 PRECEDENT study of dalzanemdor for the treatment of people with mild cognitive impairment in Parkinson&#8217;s Disease.</li>
<li>DocGo Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCGO#NASDAQ">DCGO</a>) shares fell 5.5% to $3.23 in pre-market trading.</li>
<li>Sunnova Energy International Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) fell 4.5% to $3.61 in pre-market trading.</li>
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) fell 3.8% to $3.85 in pre-market trading.</li>
<li>ON Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) shares fell 2.9% to $61.13 in pre-market trading after Exane BNP Paribas downgraded the stock from Neutral to Underperform.</li>
</ul>

Read More: <a href="https://www.benzinga.com/news/earnings/24/04/38329059/netflix-procter-gamble-and-3-stocks-to-watch-heading-into-friday">Netflix, Procter &amp; Gamble And 3 Stocks To Watch Heading Into Friday</a>

Netflix, ON Semiconductor And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Scotiabank analyst George Farmer maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Sector Outperform and lowers the price target from $34 to $19.

Scotiabank Maintains Sector Outperform on Sage Therapeutics, Lowers Price Target to $19

Oppenheimer analyst Jay Olson maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Perform and lowers the price target from $25 to $17.

Oppenheimer Maintains Perform on Sage Therapeutics, Lowers Price Target to $17

Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $23.67, with a high estimate of $29.00 and a low estimate of $14.00. Experiencing a 1.37% decline, the current average is now lower than the previous average price target of $24.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1713441646_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Sage Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$16.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$28.00</td>
<td>-</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$24.00</td>
<td>-</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$14.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$29.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$26.00</td>
<td>-</td>
</tr>
<tr>
<td>Vikram Purohit</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$26.00</td>
<td>$21.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Sage Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Sage Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Sage Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SAGE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sage Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Sage Therapeutics Better</h2>
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
<h3>Sage Therapeutics's Financial Performance</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Positive Revenue Trend: Examining Sage Therapeutics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2621.54% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Sage Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -41.95%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Sage Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -4.05%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -3.57%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.01, Sage Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Examination Of 9 Analyst Recommendations For Sage Therapeutics

TD Cowen analyst Ritu Baral maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Buy and lowers the price target from $30 to $16.

TD Cowen Maintains Buy on Sage Therapeutics, Lowers Price Target to $16

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Neutral and maintains $28 price target.

HC Wainwright & Co. Reiterates Neutral on Sage Therapeutics, Maintains $28 Price Target

Wedbush analyst Laura Chico reiterates Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Neutral and maintains $24 price target.

Wedbush Reiterates Neutral on Sage Therapeutics, Maintains $24 Price Target

Sage Therapeutics, Inc.	(SAGE) Q1 2024 Earnings Call Transcript

In a report released today, Joon Lee from Truist Financial maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price tar...

Hold Rating on SAGE Therapeutics Amid Limited Revenue Prospects and Pipeline Uncertainty

Analyst Uy Ear of Mizuho Securities maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), retaining the price target of $20.00. U...

SAGE Therapeutics' Zurzuvae Sales Exceed Expectations but Uncertainties Prompt Hold Rating

Analyst Tazeen Ahmad of Bank of America Securities reiterated a Sell rating on SAGE Therapeutics (SAGE – Research Report), retaining the price targ...

Sell Rating on Sage Therapeutics Amid Zurzuvae Sales Concerns and Pipeline Risks

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a pric...

SAGE Therapeutics (SAGE) Receives a Hold from RBC Capital

SAGE Therapeutics (SAGE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Sumant Kulkarn...

Balancing Opportunity and Risk: Hold Rating on SAGE Therapeutics Amidst High-Stakes Catalysts and Financial Reassessment

In a report released today, Douglas Tsao from H.C. Wainwright maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price ...

SAGE Therapeutics: Hold Rating Amidst Zurzuvae Success and Dalzanemdor Setbacks

Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Teladoc (TDOC – Research Report), Gilead Sciences ...

Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Gilead Sciences (GILD) and SAGE Therapeutics (SAGE)

According to the National Institute of Health, around one in seven women can develop postpartum depression following childbirth. Until recently, th...

Novel Postpartum Depression Treatment Offers Upside Potential for Sage Therapeutics (NASDAQ:SAGE)

BIIB

GILD

TDOC

Press Releases

Sage Therapeutics Announces Changes to Board of Directors

Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference

Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024

Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress

Sage Therapeutics to Present at Upcoming March Investor Conferences

Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024

Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Sage Therapeutics Stock (NASDAQ:SAGE), Short Interest Report

People Also Watch